Coherus Oncology dismisses Ernst & Young, appoints PwC as auditor
Coherus Oncology's Audit Committee dismissed Ernst & Young LLP as its independent registered public accounting firm on June 12, 2026, effective immediately. PricewaterhouseCoopers LLP was selected the same day to serve as auditor for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures. EY's audit reports on the Company's consolidated financial statements for fiscal years 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications; no disagreements on accounting principles or auditing procedures existed during the fiscal years 2025 and 2024 and the subsequent interim period through the dismissal date.
Key facts
- Ernst & Young LLP dismissed as independent registered public accounting firm, June 12, 2026
- PricewaterhouseCoopers LLP selected as new auditor for fiscal year ending December 31, 2026
- Material weakness in internal control over financial reporting related to inventory account reconciliations disclosed in Form 10-K for year ended December 31, 2024, filed March 17, 2025
- Management concluded in Form 10-K for year ended December 31, 2025 (filed March 9, 2026) that material weakness had been remediated
- No disagreements with EY on accounting principles, financial statement disclosure, or auditing scope during fiscal years 2025 and 2024 and interim period through dismissal
Why it matters
The auditor transition from a Big Four firm to another Big Four firm, combined with the prior-year material weakness in inventory controls that management reported as remediated, may signal completion of a control remediation cycle and a routine auditor relationship change rather than distress.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-15. Not investment advice. View the source filing on SEC.gov →